Has Your Doctor Told You About The 400 Published Studies On Ivermectin And Cancer?

The Big Money Battle Over Dewormer Drugs and Cancer

For decades, certain inexpensive antiparasitic drugs have been hiding in plain sight, showing surprising promise against some of the deadliest cancers.

Yet instead of embracing these discoveries, more and more critics are saying the medical establishment has worked to suppress them—protecting profits over patients. At the center of this controversy are three off-patent drugs: ivermectin, fenbendazole, and mebendazole.

A Pre-Planned Blockade

During the COVID-19 pandemic, Johns Hopkins University—considered by many the most influential cancer research institution in the world—was awarded a patent for the use of mebendazole in treating brain cancers.

This move stunned some observers, because mebendazole is already FDA-approved and could be prescribed off-label immediately. Instead, the patent effectively gave the institution control over its potential use against cancer.

At the same time, Dr. William Makis has suggested that CVS and Walgreens received $2.2 billion during the pandemic… not to dispense ivermectin, even when doctors prescribed it. Critics saw this as part of a premeditated effort to keep these low-cost drugs out of circulation for anything beyond their original uses.

Off-Patent, Off-Limits

Ivermectin lost its patent protection in 1996, with fenbendazole following around the same time. As generics, they are cheap to produce—too cheap, many argue, to generate profits for the multi-billion-dollar cancer industry. This, some believe, explains why promising preclinical research from the last 15 years has been largely ignored.

That research is not trivial. There are nearly 400 published studies exploring ivermectin’s potential in cancer treatment, ranging from cell cultures to animal models and even a handful of human studies. Similar findings exist for fenbendazole and mebendazole, yet mainstream oncology has shown little interest. Follow the money, or maybe follow the lack of money in this case.

Discovering a Hidden Cancer Tool

Originally investigated by one doctor as a potential COVID-19 treatment, ivermectin’s benefits soon appeared to extend far beyond viral infections. When patients facing “turbo cancers”—extremely aggressive cases often reported after vaccination—began seeking advice, the doctor turned to the anti-cancer mechanisms described in ivermectin research.

What followed was striking. Stage-four cancer patients who were told they had no options began reporting tumor shrinkage and improved health after using ivermectin, sometimes alongside fenbendazole or mebendazole. Word spread quickly, leading to the creation of what is now the largest ivermectin cancer clinic in the world, treating over 6,000 patients.

Combining Dewormers for Cancer Care

Patient experiences led to formal study. In 2024, the clinic published its first peer-reviewed paper proposing safe dosing strategies for using ivermectin, fenbendazole, and mebendazole—individually or in combination—for cancer patients. The paper drew on real-world results, where patients with previously terminal diagnoses were still alive and managing their disease.

The drugs themselves come from different corners of medicine. Ivermectin is an antiparasitic for both humans and animals. Fenbendazole is used in dogs, while mebendazole is used in humans. All three share similar structures and, more importantly, appear to act on cancer cells through multiple pathways.

How They Work

Each drug has roughly a dozen identified mechanisms against cancer. Ivermectin, for instance, targets cancer stem cells, which are responsible for regrowth and resistance to therapy. It can reverse chemotherapy resistance by reprogramming cancer cells, block tumor proliferation pathways, and inhibit viral replication. In benign conditions, it has been observed to shrink fibroids and other non-cancerous growths by shutting down overactive cell proliferation.

Scientific studies now confirm that ivermectin attacks cancer at its molecular “command centers.” It disrupts critical survival pathways like Wnt/β-Catenin, which fuels tumor growth and spread; Akt/mTOR, which manages nutrient use and energy; and NF-κB, which helps tumors avoid death and thrive in inflammation. By shutting down these systems, ivermectin can force cancer cells into apoptosis—their programmed self-destruct sequence—while slowing or stopping metastasis.

It also impairs the PAK1 pathway, which cancer cells use to move and invade other tissues, and interferes with integrin β1/FAK signaling, making it harder for tumors to anchor and colonize new areas. Another key target is the purinergic (P2X7) receptor, which ivermectin activates to help immune cells kill tumors more effectively.

The Role of Oxidative Stress

One of ivermectin’s most potent anti-cancer weapons is oxidative stress. Cancer cells already operate with higher baseline levels of reactive oxygen species (ROS) than normal cells, making them vulnerable to any extra oxidative push. Ivermectin increases ROS production, damages mitochondria—the cell’s power plants—depletes protective antioxidants like glutathione, and triggers DNA damage. This combination can starve cancer cells of energy and overwhelm their repair systems.

The downstream effects are sweeping: cancer cells stop dividing, blood vessel growth to the tumor slows, drug resistance can reverse, and the immune system can launch more effective attacks. This oxidative stress also contributes to reducing cancer-friendly inflammation, lowering key inflammatory cytokines like IL-6 and TNF-α while boosting protective anti-inflammatory signals.

Selective Action on Diseased Cells

Animal studies show ivermectin’s ability to selectively target diseased cells while leaving healthy cells unharmed. In one experiment, mice with lymphoma in their spleens saw tumor cells eliminated while normal spleen tissue remained intact.

This selectivity extends beyond cancer. Some patients have reported resolution of long-standing benign conditions, such as uterine fibroids, likely because ivermectin shuts down the same growth pathways in non-cancerous tumors.

A Drug With a Remarkable History

Ivermectin’s story began in the 1970s when a Japanese scientist discovered it in a bacterium found on a golf course. Initially developed for veterinary use, it soon proved effective in humans against parasitic infections. In 2015, it earned the Nobel Prize in Physiology or Medicine, alongside the antiparasitic herb Artemisia annua (sweet wormwood). Both substances, researchers have since found, also have potential activity against certain cancers.

Yet in the public mind, ivermectin has been reduced to “horse paste” by media ridicule, despite decades of safe use in humans and billions of doses distributed worldwide.

Global Implications and Japan’s Crisis

Beyond cancer, ivermectin’s suppression during COVID-19 remains controversial. Japan, for example, now faces its highest excess mortality since World War II, which some physicians attribute to aggressive mRNA vaccine campaigns. In 2023, visiting physicians warned the Japanese government against rolling out experimental self-amplifying mRNA vaccines without proper testing. According to insiders, there were no studies on shedding or environmental spread, yet the rollout proceeded.

In this environment, where lifesaving interventions may be overlooked or actively blocked, advocates for drugs like ivermectin see a pattern: health policy shaped less by evidence and more by control.

A Knowledge Known for Decades

Long before academic papers appeared, country veterinarians and rural communities suspected dewormers had broader benefits. Stories go back decades, with farmers noting better health after taking veterinary formulations themselves. While not a safe or controlled practice, these anecdotes echo what modern research now documents: these drugs can act in ways far beyond parasite control.

This “folk knowledge” never translated into mainstream medicine, largely because such inexpensive solutions have no commercial incentive in a profit-driven healthcare system.

Publishing the Evidence

In recent years, patient testimonials have been compiled and shared online, showing folks surviving aggressive cancers far longer than predicted. A newly published case series on fenbendazole marks the second largest of its kind since a landmark Stanford study in 2021.

These publications aim to legitimize the discussion and encourage further research, though advocates remain wary that patents and profit motives will continue to stifle progress.

The Larger Question

The controversy over ivermectin, fenbendazole, and mebendazole forces a deeper question: should promising, low-cost treatments be pursued vigorously even when they disrupt established financial models? Or will they remain buried beneath patents, regulatory barriers, and public ridicule?

For those who credit these drugs with saving their lives, the answer is obvious. The challenge is convincing a medical establishment that may have more to lose than to gain from acknowledging them.

Ask your doctor if any of the drugs mentioned in this article are right for you.

Source: https://www.offthegridnews.com/what-they-dont-want-you-to-know/has-your-doctor-told-you-about-the-400-published-studies-on-ivermectin-and-cancer/